Denali Therapeutics Financial Statements (DNLI)
|
|
Report date
|
|
|
27.02.2020 |
26.02.2021 |
28.02.2022 |
27.02.2023 |
28.02.2024 |
|
06.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
26.7 |
335.7 |
48.7 |
108.5 |
330.5 |
|
305.0 |
Operating Income, bln rub |
|
|
-213.2 |
62.7 |
-295.8 |
-340.7 |
-196.7 |
|
-504.6 |
EBITDA, bln rub |
? |
|
-205.2 |
62.7 |
-287.2 |
-330.4 |
-180.0 |
|
-498.3 |
Net profit, bln rub |
? |
|
-197.6 |
71.1 |
-290.6 |
-326.0 |
-145.2 |
|
-427.5 |
|
OCF, bln rub |
? |
|
-151.6 |
416.2 |
-211.4 |
-244.7 |
-358.0 |
|
-362.6 |
CAPEX, bln rub |
? |
|
17.9 |
3.10 |
8.50 |
17.8 |
12.9 |
|
13.1 |
FCF, bln rub |
? |
|
-169.5 |
413.1 |
-219.9 |
-262.5 |
-370.9 |
|
-375.7 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
239.9 |
272.9 |
344.4 |
449.2 |
527.2 |
|
498.3 |
Cost of production, bln rub |
|
|
193.4 |
212.6 |
5.61 |
7.03 |
423.9 |
|
6.28 |
R&D, bln rub |
|
|
193.4 |
212.6 |
265.4 |
358.7 |
423.9 |
|
404.5 |
Interest expenses, bln rub |
|
|
15.2 |
0.000 |
0.000 |
14.8 |
0.000 |
|
21.1 |
|
Assets, bln rub |
|
|
553.2 |
1 604 |
1 404 |
1 460 |
1 154 |
|
1 454 |
Net Assets, bln rub |
? |
|
394.9 |
1 151 |
962.3 |
1 042 |
1 031 |
|
1 318 |
Debt, bln rub |
|
|
68.9 |
64.2 |
58.6 |
60.4 |
52.2 |
|
52.5 |
Cash, bln rub |
|
|
415.4 |
1 470 |
865.4 |
1 336 |
1 035 |
|
836.6 |
Net debt, bln rub |
|
|
-346.5 |
-1 406 |
-806.9 |
-1 276 |
-982.3 |
|
-784.0 |
|
Ordinary share price, rub |
|
|
17.4 |
83.8 |
44.6 |
27.8 |
21.5 |
|
19.6 |
Number of ordinary shares, mln |
|
|
95.6 |
109.0 |
121.5 |
125.5 |
137.4 |
|
169.5 |
|
Market cap, bln rub |
|
|
1 665 |
9 128 |
5 420 |
3 491 |
2 948 |
|
3 323 |
EV, bln rub |
? |
|
1 319 |
7 722 |
4 613 |
2 215 |
1 966 |
|
2 539 |
Book value, bln rub |
|
|
395 |
1 151 |
962 |
1 042 |
1 031 |
|
1 318 |
|
EPS, rub |
? |
|
-2.07 |
0.65 |
-2.39 |
-2.60 |
-1.06 |
|
-2.52 |
FCF/share, rub |
|
|
-1.77 |
3.79 |
-1.81 |
-2.09 |
-2.70 |
|
-2.22 |
BV/share, rub |
|
|
4.13 |
10.6 |
7.92 |
8.30 |
7.50 |
|
7.78 |
|
EBITDA margin, % |
? |
|
-769.1% |
18.7% |
-590.1% |
-304.6% |
-54.4% |
|
-163.4% |
Net margin, % |
? |
|
-740.7% |
21.2% |
-597.2% |
-300.6% |
-43.9% |
|
-140.1% |
FCF yield, % |
? |
|
-10.2% |
4.53% |
-4.06% |
-7.52% |
-12.6% |
|
-11.3% |
ROE, % |
? |
|
-50.0% |
6.18% |
-30.2% |
-31.3% |
-14.1% |
|
-32.4% |
ROA, % |
? |
|
-35.7% |
4.43% |
-20.7% |
-22.3% |
-12.6% |
|
-29.4% |
|
P/E |
? |
|
-8.43 |
128.3 |
-18.7 |
-10.7 |
-20.3 |
|
-7.77 |
P/FCF |
|
|
-9.83 |
22.1 |
-24.6 |
-13.3 |
-7.95 |
|
-8.85 |
P/S |
? |
|
62.4 |
27.2 |
111.4 |
32.2 |
8.92 |
|
10.9 |
P/BV |
? |
|
4.22 |
7.93 |
5.63 |
3.35 |
2.86 |
|
2.52 |
EV/EBITDA |
? |
|
-6.43 |
123.1 |
-16.1 |
-6.71 |
-10.9 |
|
-5.10 |
Debt/EBITDA |
|
|
1.69 |
-22.4 |
2.81 |
3.86 |
5.46 |
|
1.57 |
|
R&D/CAPEX, % |
|
|
1 079% |
6 870% |
3 122% |
2 012% |
3 276% |
|
3 098% |
|
CAPEX/Revenue, % |
|
|
67.2% |
0.92% |
17.5% |
16.4% |
3.91% |
|
4.28% |
|
Denali Therapeutics shareholders |